Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novocure Ltd NVCR

Healthcare Medical Devices
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and... see more

Recent & Breaking News (NDAQ:NVCR)

Novocure Secures New $150 Million Non-Dilutive Term Loan Financing

Business Wire February 7, 2018

Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director

GlobeNewswire February 5, 2018

JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival without Negatively Influencing Health-Related Quality of Life Compared to Temozolomide Alone in Newly Diagnosed GBM Patients

Business Wire February 1, 2018

Novocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue

Business Wire January 9, 2018

Novocure to Participate in 36th Annual J.P. Morgan Healthcare Conference

Business Wire December 20, 2017

JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma

Business Wire December 19, 2017

Novocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic Cancer

Business Wire December 18, 2017

Stock Review for Medical Equipment's Investors -- Prestige Brands, Senseonics, NovoCure, and Varian Medical Systems

PR Newswire December 14, 2017

Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors

GlobeNewswire December 11, 2017

Novocure Receives Reimbursement Approval for Optune® in Japan for the Treatment of Newly Diagnosed Glioblastoma

Business Wire December 1, 2017

Novocure to Present at Two Upcoming Investor Conferences in December

Business Wire November 22, 2017

Investor Expectations to Drive Momentum within Vector Group, NovoCure, ORBCOMM, Ecolab, Bank of America, and Viking Therapeutics — Discovering Underlying Factors of Influence

GlobeNewswire November 20, 2017

Patients Who Used Optune® More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocure’s EF-14 Trial: A Median Survival of 24.9 Months from Randomization and a Five-Year Survival of 29.3 Percent

Business Wire November 17, 2017

Novocure Announces 28 Presentations on Tumor Treating Fields from Externally Led Clinical Research and Analysis at 22nd Annual Meeting of the Society for Neuro-Oncology

Business Wire November 13, 2017

Novocure Announces 10 Presentations on Simulation Studies Aiming to Optimize Treatment Delivery of Tumor Treating Fields at 22nd Annual Meeting of the Society for Neuro-Oncology

Business Wire November 9, 2017

Novocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields’ Mechanism of Action at 22nd Annual Meeting of the Society for Neuro-Oncology

Business Wire November 8, 2017

Novocure Announces Six Clinical Presentations on Novocure’s Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology

Business Wire November 6, 2017

Novocure Reports Third Quarter 2017 Financial Results and Provides Company Update

Business Wire October 26, 2017

Novocure Announces Data Presentations at the IASLC 18th World Conference on Lung Cancer

Business Wire October 16, 2017

Today's Research Report Coverage on Medical Equipment Stocks -- Varian Medical Systems, Senseonics, Xtant Medical, and NovoCure

PR Newswire October 6, 2017